Braveheart Bio’s IPO terms, priced at an upsized $18 per share on August 5 with Fidelity anchoring 25% of the deal, anchor trader expectations for a closing market capitalization near $1.15–1.3 billion. The clinical-stage biotech’s lead asset BHB-1893, in-licensed from Hengrui, targets hypertrophic cardiomyopathy with Phase 3 trials slated for late 2026, supported by positive Phase 2 data and zero revenue offset by a net loss of roughly $80 million. Strong institutional demand and a rebounding biotech IPO environment in 2026 have narrowed the gap between the $1.15–1.3 billion, $1.3–1.45 billion, $1.45–1.6 billion, and $1.6 billion-plus brackets, each carrying 20–30% implied probability. Resolution hinges on first-day trading volume, peer valuations in the cardiovascular space, and any last-minute order flow shifts before the August 7 close.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於11.5億美元-13億美元 31%
16 億美元以上 25%
13億美元-14.5億美元 22%
14.5 億美元–16 億美元 20%
最新
最新
2026-08-06
低於10億美元
<1%
10億-11.5億美元
8%
11.5億美元-13億美元
31%
13億美元-14.5億美元
22%
14.5 億美元–16 億美元
20%
16 億美元以上
26%
2026年10月前不上市
2%
11.5億美元-13億美元 31%
16 億美元以上 25%
13億美元-14.5億美元 22%
14.5 億美元–16 億美元 20%
最新
最新
2026-08-06
低於10億美元
$50 交易量
<1%
10億-11.5億美元
$471 交易量
8%
11.5億美元-13億美元
$282 交易量
31%
13億美元-14.5億美元
$181 交易量
22%
14.5 億美元–16 億美元
$320 交易量
20%
16 億美元以上
$312 交易量
26%
2026年10月前不上市
$205 交易量
2%
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Braveheart Bio’s IPO terms, priced at an upsized $18 per share on August 5 with Fidelity anchoring 25% of the deal, anchor trader expectations for a closing market capitalization near $1.15–1.3 billion. The clinical-stage biotech’s lead asset BHB-1893, in-licensed from Hengrui, targets hypertrophic cardiomyopathy with Phase 3 trials slated for late 2026, supported by positive Phase 2 data and zero revenue offset by a net loss of roughly $80 million. Strong institutional demand and a rebounding biotech IPO environment in 2026 have narrowed the gap between the $1.15–1.3 billion, $1.3–1.45 billion, $1.45–1.6 billion, and $1.6 billion-plus brackets, each carrying 20–30% implied probability. Resolution hinges on first-day trading volume, peer valuations in the cardiovascular space, and any last-minute order flow shifts before the August 7 close.
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
市場開放時間： Aug 5, 2026, 5:48 AM ET
交易量
$1,821結束日期
2026-08-06市場開放時間
Aug 5, 2026, 5:48 AM ETResolver
0x69c47De9D...This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Braveheart Bio’s IPO terms, priced at an upsized $18 per share on August 5 with Fidelity anchoring 25% of the deal, anchor trader expectations for a closing market capitalization near $1.15–1.3 billion. The clinical-stage biotech’s lead asset BHB-1893, in-licensed from Hengrui, targets hypertrophic cardiomyopathy with Phase 3 trials slated for late 2026, supported by positive Phase 2 data and zero revenue offset by a net loss of roughly $80 million. Strong institutional demand and a rebounding biotech IPO environment in 2026 have narrowed the gap between the $1.15–1.3 billion, $1.3–1.45 billion, $1.45–1.6 billion, and $1.6 billion-plus brackets, each carrying 20–30% implied probability. Resolution hinges on first-day trading volume, peer valuations in the cardiovascular space, and any last-minute order flow shifts before the August 7 close.
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
交易量
$1,821結束日期
2026-08-06市場開放時間
Aug 5, 2026, 5:48 AM ETResolver
0x69c47De9D...Braveheart Bio’s IPO terms, priced at an upsized $18 per share on August 5 with Fidelity anchoring 25% of the deal, anchor trader expectations for a closing market capitalization near $1.15–1.3 billion. The clinical-stage biotech’s lead asset BHB-1893, in-licensed from Hengrui, targets hypertrophic cardiomyopathy with Phase 3 trials slated for late 2026, supported by positive Phase 2 data and zero revenue offset by a net loss of roughly $80 million. Strong institutional demand and a rebounding biotech IPO environment in 2026 have narrowed the gap between the $1.15–1.3 billion, $1.3–1.45 billion, $1.45–1.6 billion, and $1.6 billion-plus brackets, each carrying 20–30% implied probability. Resolution hinges on first-day trading volume, peer valuations in the cardiovascular space, and any last-minute order flow shifts before the August 7 close.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions